OGXI Share Price

Open 0.47 Change Price %
High 0.48 1 Day -0.02 -4.76
Low 0.40 1 Week 0.00 0.00
Close 0.40 1 Month 0.00 0.00
Volume 661692 1 Year -0.09 -18.37
52 Week High 0.93
52 Week Low 0.33
OGXI Important Levels
Resistance 2 0.47
Resistance 1 0.44
Pivot 0.43
Support 1 0.36
Support 2 0.33
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
QQQ 142.81 -1.05%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
LOCM 0.09 50.00%
PTSX 0.07 40.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
HMNY 8.36 19.94%
IPCI 1.01 18.82%
ACRX 3.91 16.72%
More..
NASDAQ USA Top Losers Stocks
CAFI 0.00 -100.00%
DEER 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CPWR 1.00 -60.00%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

OncoGenex Pharmaceuticals Inc. (NASDAQ: OGXI)

OGXI Technical Analysis 2
As on 2nd Aug 2017 OGXI Share Price closed @ 0.40 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.46 & Buy for SHORT-TERM with Stoploss of 0.38 we also expect STOCK to react on Following IMPORTANT LEVELS.
OGXI Target for September
1st Target up-side 0.44
2nd Target up-side 0.47
3rd Target up-side 0.5
1st Target down-side 0.36
2nd Target down-side 0.33
3rd Target down-side 0.3
OGXI Other Details
Segment EQ
Market Capital 178379728.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.oncogenex.com
OGXI Address
OGXI
1522- 217th Place SE
Suite 100
Bothell, WA 98021
United States
Phone: 425-686-1500
OGXI Latest News
Interactive Technical Analysis Chart OncoGenex Pharmaceuticals Inc. ( OGXI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on OncoGenex Pharmaceuticals Inc.
OGXI Business Profile
OncoGenex Pharmaceuticals, Inc. (OncoGenex) is a biopharmaceutical company engaged in the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. The Company has four product candidates in its pipeline: custirsen, OGX-427, OGX-225 and CSP-9222. Of the product candidates in its pipeline, custirsen and OGX-427 are clinical-stage assets. The Company�s product candidates custirsen, OGX-427, and OGX-225 focus on mechanisms of treatment resistance in cancer patients and are designed to block the production of specific proteins that promote survival of tumor cells, and are over-produced in response to a variety of cancer treatments. Product candidate CSP-9222 is the lead compound from a family of caspase activators that have been in-licensed from Bayer and demonstrate activation of programmed cell death in pre-clinical models.